These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 24090952)

  • 1. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure.
    Hrynchyshyn N; Jourdain P; Desnos M; Diebold B; Funck F
    Arch Cardiovasc Dis; 2013 Oct; 106(10):541-6. PubMed ID: 24090952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?
    Srivatsan V; George M; Shanmugam E
    Eur J Prev Cardiol; 2015 Sep; 22(9):1096-110. PubMed ID: 25268020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
    Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute cardiac dyspnea in the emergency department: diagnostic value of N-terminal prohormone of brain natriuretic peptide and galectin-3.
    Stoica A; Şorodoc V; Lionte C; Jaba IM; Costache I; Anisie E; Tuchiluș C; Rusalim Petriș O; Sîrbu O; Jaba E; Ceasovschih A; Vâţă L; Şorodoc L
    J Int Med Res; 2019 Jan; 47(1):159-172. PubMed ID: 30222016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.
    Felker GM; Fiuzat M; Shaw LK; Clare R; Whellan DJ; Bettari L; Shirolkar SC; Donahue M; Kitzman DW; Zannad F; Piña IL; O'Connor CM
    Circ Heart Fail; 2012 Jan; 5(1):72-8. PubMed ID: 22016505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure.
    French B; Wang L; Ky B; Brandimarto J; Basuray A; Fang JC; Sweitzer NK; Cappola TP
    J Card Fail; 2016 Apr; 22(4):256-62. PubMed ID: 26571149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.
    van der Velde AR; Gullestad L; Ueland T; Aukrust P; Guo Y; Adourian A; Muntendam P; van Veldhuisen DJ; de Boer RA
    Circ Heart Fail; 2013 Mar; 6(2):219-26. PubMed ID: 23395934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
    Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
    Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.
    van Kimmenade RR; Januzzi JL; Ellinor PT; Sharma UC; Bakker JA; Low AF; Martinez A; Crijns HJ; MacRae CA; Menheere PP; Pinto YM
    J Am Coll Cardiol; 2006 Sep; 48(6):1217-24. PubMed ID: 16979009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of serum levels of high sensitivity troponin T, galectin-3 and C-terminal propeptide of type I procollagen at long term follow-up in heart failure patients with reduced ejection fraction: Comparison with soluble AXL and BNP.
    Batlle M; Campos B; Farrero M; Cardona M; González B; Castel MA; Ortiz J; Roig E; Pulgarín MJ; Ramírez J; Bedini JL; Sabaté M; García de Frutos P; Pérez-Villa F
    Int J Cardiol; 2016 Dec; 225():113-119. PubMed ID: 27718443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction.
    Carrasco-Sánchez FJ; Aramburu-Bodas O; Salamanca-Bautista P; Morales-Rull JL; Galisteo-Almeda L; Páez-Rubio MI; Arias-Jiménez JL; Aguayo-Canela M; Pérez-Calvo JI
    Int J Cardiol; 2013 Nov; 169(3):177-82. PubMed ID: 24207066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure.
    Jungbauer CG; Riedlinger J; Block D; Stadler S; Birner C; Buesing M; König W; Riegger G; Maier L; Luchner A
    Biomark Med; 2014; 8(6):777-89. PubMed ID: 25224934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure.
    Miller WL; Saenger AK; Grill DE; Slusser JP; Bayes-Genis A; Jaffe AS
    J Card Fail; 2016 Apr; 22(4):249-55. PubMed ID: 26277907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.
    Lok DJ; Van Der Meer P; de la Porte PW; Lipsic E; Van Wijngaarden J; Hillege HL; van Veldhuisen DJ
    Clin Res Cardiol; 2010 May; 99(5):323-8. PubMed ID: 20130888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure.
    Stoltze Gaborit F; Bosselmann H; Kistorp C; Iversen K; Kumler T; Gustafsson F; Goetze JP; Sölétormos G; Tønder N; Schou M
    BMC Cardiovasc Disord; 2016 May; 16():117. PubMed ID: 27246703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure.
    Mueller T; Gegenhuber A; Leitner I; Poelz W; Haltmayer M; Dieplinger B
    Clin Chim Acta; 2016 Dec; 463():158-164. PubMed ID: 27983996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive value of plasma biomarkers in discharged heart failure patients: role of galectin-3.
    Leone M; Iacoviello M
    Minerva Cardioangiol; 2016 Apr; 64(2):181-94. PubMed ID: 26426300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The involvement of galectin-3 in heart failure].
    Kałan M; Witczak A; Mosiewicz J; Donica H
    Postepy Hig Med Dosw (Online); 2015 Sep; 69():1107-13. PubMed ID: 26400896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure.
    Lok DJ; Klip IT; Lok SI; Bruggink-André de la Porte PW; Badings E; van Wijngaarden J; Voors AA; de Boer RA; van Veldhuisen DJ; van der Meer P
    Am J Cardiol; 2013 Sep; 112(6):831-7. PubMed ID: 23820571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.